自体干细胞卵巢移植提高低反应患者生育潜能
该前瞻性观察性先导研究纳入17例预后极差的低反应患者,行骨髓来源干细胞卵巢输注(ASCOT),以窦卵泡计数(AFC)和抗苗勒管激素(AMH)评估卵巢储备及IVF结局。ASCOT后2周AFC显著改善,81.3%患者卵巢功能改善,获5例妊娠,但胚胎整倍体率低(16.1%)。
要点
- ASCOT后2周AFC显著改善,81.3%患者卵巢功能改善。
- 控制性卵巢刺激后获卵数增加,但胚胎整倍体率低(16.1%)。
- 共获5例妊娠:2例胚胎移植后,3例自然受孕。
核心结论
- ASCOT可能优化了现有卵泡的动员和生长,可能与血浆分离产物中的成纤维细胞生长因子-2和血小板反应蛋白-1有关。
- ASCOT改善了低反应患者的卵泡和卵母细胞数量,使先前仅限于卵母细胞捐赠的妇女得以妊娠。
研究设计与样本
- 前瞻性观察性先导研究,在大学医院开展,纳入17例低反应患者,干预为骨髓来源干细胞卵巢输注,临床试验注册号NCT02240342。
主要发现
- ASCOT后2周AFC显著改善。
- 以AFC增加3个或以上卵泡和/或AMH连续两次升高为成功标准,81.3%的妇女卵巢功能改善。
- 这些积极效应与成纤维细胞生长因子-2和血小板反应蛋白的存在相关。
- 控制性卵巢刺激期间,ASCOT增加了可刺激窦卵泡和卵母细胞数量,但胚胎整倍体率低(16.1%)。
- 共获5例妊娠:2例胚胎移植后,3例自然受孕。
关键数值与推荐
- 成功标准为AFC增加3个或以上卵泡和/或AMH连续两次升高,81.3%的妇女达到卵巢功能改善。
- 胚胎整倍体率为16.1%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate effects of autologous stem cell ovarian transplant (ASCOT) on ovarian reserve and IVF outcomes of women who are poor responders with very poor prognosis. DESIGN: Prospective observational pilot study. SETTING: University hospital. PATIENT(S): Seventeen women who are poor responders. INTERVENTION(S): Ovarian infusion of bone marrow-derived stem cells. MAIN OUTCOME MEASURE(S): Serum antimüllerian hormone levels and antral follicular count (AFC), punctured follicles, and oocytes retrieved after stimulation (controlled ovarian stimulation) were measred. Apheresis was analyzed for growth factor concentrations. RESULT(S): The ASCOT resulted in a significant improvement in AFC 2 weeks after treatment. With an increase in AFC of three or more follicles and/or two consecutive increases in antimüllerian hormone levels as success criteria, ovarian function improved in 81.3% of women. These positive effects were associated with the presence of fibroblast growth factor-2 and thrombospondin. During controlled ovarian stimulation, ASCOT increased the number of stimulable antral follicles and oocytes, but the embryo euploidy rate was low (16.1%). Five pregnancies were achieved: two after ET, three by natural conception. CONCLUSION(S): Our results suggest that ASCOT optimized the mobilization and growth of existing follicles, possibly related to fibroblast growth factor-2 and thrombospondin-1 within apheresis. The ASCOT improved follicle and oocyte quantity enabling pregnancy in women who are poor responders previously limited to oocyte donation. CLINICAL TRIAL REGISTRATION NUMBER: NCT02240342.
引用
- Herraiz S, Romeu M, Buigues A, et al. Autologous stem cell ovarian transplantation to increase reproductive potential in patients who are poor responders. Fertil Steril. 2018. PMID: 29960701. doi:10.1016/j.fertnstert.2018.04.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。